Ali Kocataş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ali Kocataş has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Ayça Sultan Şahin
Department of Anesthesiology and Reanimation, University of Health Sciences, Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Turkey
3 shared publications - Ebru Kaya
Istanbul Health Science University Kanuni Sultan Süleyman Education and Training Hospital, Department of Anesthesiology, Istanbul, Turkey
3 shared publications - Mehmet Abdussamet Bozkurt
İstinye University
3 shared publications - Eyüp Gemici
University of Health Sciences, Turkey
2 shared publications - Hasan Onal
Department of Pediatrics, Başakşehir Çam and Sakura City Hospital, University of Health Sciences, İstanbul, Türkiye
2 shared publications - Kemal Dolay
Department of General Surgery and Intestinal Endoscopy, Dolay Clinic, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 12 March 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (4) , 103418
Angiotensin (1−7) peptide replacement therapy with plasma transfusion in COVID-19
- 12 March 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (4) , 103418
Open AccessAngiotensin (1−7) peptide replacement therapy with plasma transfusion in COVID-19
- Open Access
- 20 January 2022
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 19 (2) , em357
Clinic Evaluation of The Destrovir Spray Effectiveness in SARS-CoV-2 Disease
In late 2019 on 11th March 2020 a novel coronavirus, SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) appeared in Wuhan, China and World Health Organisation declared it to have developed pandemic status. Although there are many detection techniques for the disease to control the pandemic such as RT-PCR, serological methods, or fast antigen tests, the actual problem is the prevention of the disease. The nasal cavity and rhino pharynx are key sites of the initial replication of SARS-CoV-2. In this article, the effectiveness of destrovir spray was investigated by creating a mechanical barrier in the nasal and oral mucosa, which are the entry points of the virus into the body, and to destroy the virus that comes into contact with this barrier. In the presented study, quantitation cycle (Cq) and irradiation values (RFU) of 12 different high-positive patients (Cq≤25) after application of both RT-PCR and destrovir spray were determined at different concentrations (10%, 20%, 30%, 40%, and 50%) aimed to evaluate its effectiveness. According to the results obtained by comparing the effectiveness of disinfectant with 70% ethyl alcohol on the 46 patient samples with Cq<20, 46 patient samples with Cq values between 20-25, and 46 patient samples with Cq≥25 including different variants are examined. A total of 138 COVID-19 patient samples were treated with 5% and 10% ratios of destrovir spray. Its effectiveness on Cq values and RFU was evaluated and it was aimed to compare the effectiveness of this evaluation with 96% ethyl alcohol used in the same samples.
- 20 January 2022
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 19 (2) , em357
Open AccessClinic Evaluation of The Destrovir Spray Effectiveness in SARS-CoV-2 Disease
In late 2019 on 11th March 2020 a novel coronavirus, SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) appeared in Wuhan, China and World Health Organisation declared it to have developed pandemic status. Although there are many detection techniques for the disease to control the pandemic such as RT-PCR, serological methods, or fast antigen tests, the actual problem is the prevention of the disease. The nasal cavity and rhino pharynx are key sites of the initial replication of SARS-CoV-2. In this article, the effectiveness of destrovir spray was investigated by creating a mechanical barrier in the nasal and oral mucosa, which are the entry points of the virus into the body, and to destroy the virus that comes into contact with this barrier. In the presented study, quantitation cycle (Cq) and irradiation values (RFU) of 12 different high-positive patients (Cq≤25) after application of both RT-PCR and destrovir spray were determined at different concentrations (10%, 20%, 30%, 40%, and 50%) aimed to evaluate its effectiveness. According to the results obtained by comparing the effectiveness of disinfectant with 70% ethyl alcohol on the 46 patient samples with Cq<20, 46 patient samples with Cq values between 20-25, and 46 patient samples with Cq≥25 including different variants are examined. A total of 138 COVID-19 patient samples were treated with 5% and 10% ratios of destrovir spray. Its effectiveness on Cq values and RFU was evaluated and it was aimed to compare the effectiveness of this evaluation with 96% ethyl alcohol used in the same samples.
- Open Access
- 1 January 2022
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 42 (1) , 5-13
Mesenchymal Stem Cell Therapy in COVID-19 Pneumonia: A Prospective, Randomized Clinical Research
Objective: Deficiencies in immune-regulatory mechanisms such as immune activation and T-regulatory cells are classically referred to as cytokine storms. Mesenchymal stem cells (MSCs) act as living anti-inflammatory cells that can rebalance cytokine/immune responses to restore balance in patients with coronavirus disease-2019 (COVID-19) acute respiratory distress syndrome by reducing the activation of T and B cells, and dendritic and natural killer cells. The aim of this study is to provide immune modulation with stem cell transplantation by reducing the damage caused and COVID-19 infection to tissues and organs. Material and Methods: In this prospective randomized single-center clinical trial, patients were divided into 3 groups: intubated without comorbidity (n=7); intubated with comorbidity (n=7); not intubated (n=7). Dosage of MSCs transplantation for each group was 1 million cell/kg intravenous at days 0, 2, and 4. age, gender, APACHE II scores, procalcitonin, C-reactive protein (CRP) and leukocyte values, and cluster of difference 4 (CD4), CD8, interleukin 2 (IL-2), and IL-6 levels, morbidities, number of days in intensive care unit, mortality were recorded. Clinical results, changes in inflammatory and immune function levels, and side effects were evaluated. Each patient's improvement in oxygenation and symptoms were recorded in the days after MSC transplantation. After treatment, lymphocyte, CRP, tumor necrosis factor-α level, and IL-6 levels were recorded. Results: There was no statistically significant difference between the three groups in terms of stem cell therapy patients' age and exit/discharge days and mortality. Patients who were in the group of 'intubated, no comorbidity' had significantly higher CD19 and CD19+HLA-DR+ values compared with patients in the groups of 'intubated with comorbidity' and 'not intubated.' CRP, FiO2, IL-6 and SpO2 values were significantly different across periods. Conclusion: Our study may found a useful effect of MSCs on severe COVID-19 pneumonia and showed reversal of hypoxia and downregulation of cytokine storm in patients with severe COVID-19 following 3 intravenous doses with no adverse effects assignable to the treatment.
- 1 January 2022
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 42 (1) , 5-13
Open AccessMesenchymal Stem Cell Therapy in COVID-19 Pneumonia: A Prospective, Randomized Clinical Research
Objective: Deficiencies in immune-regulatory mechanisms such as immune activation and T-regulatory cells are classically referred to as cytokine storms. Mesenchymal stem cells (MSCs) act as living anti-inflammatory cells that can rebalance cytokine/immune responses to restore balance in patients with coronavirus disease-2019 (COVID-19) acute respiratory distress syndrome by reducing the activation of T and B cells, and dendritic and natural killer cells. The aim of this study is to provide immune modulation with stem cell transplantation by reducing the damage caused and COVID-19 infection to tissues and organs. Material and Methods: In this prospective randomized single-center clinical trial, patients were divided into 3 groups: intubated without comorbidity (n=7); intubated with comorbidity (n=7); not intubated (n=7). Dosage of MSCs transplantation for each group was 1 million cell/kg intravenous at days 0, 2, and 4. age, gender, APACHE II scores, procalcitonin, C-reactive protein (CRP) and leukocyte values, and cluster of difference 4 (CD4), CD8, interleukin 2 (IL-2), and IL-6 levels, morbidities, number of days in intensive care unit, mortality were recorded. Clinical results, changes in inflammatory and immune function levels, and side effects were evaluated. Each patient's improvement in oxygenation and symptoms were recorded in the days after MSC transplantation. After treatment, lymphocyte, CRP, tumor necrosis factor-α level, and IL-6 levels were recorded. Results: There was no statistically significant difference between the three groups in terms of stem cell therapy patients' age and exit/discharge days and mortality. Patients who were in the group of 'intubated, no comorbidity' had significantly higher CD19 and CD19+HLA-DR+ values compared with patients in the groups of 'intubated with comorbidity' and 'not intubated.' CRP, FiO2, IL-6 and SpO2 values were significantly different across periods. Conclusion: Our study may found a useful effect of MSCs on severe COVID-19 pneumonia and showed reversal of hypoxia and downregulation of cytokine storm in patients with severe COVID-19 following 3 intravenous doses with no adverse effects assignable to the treatment.
- 20 November 2021
- Published by Galenos Yayinevi in Turkish Journal of Anaesthesiology and Reanimation
- Vol. 49 (5) , 428-429
Mesenchymal Stem Cell Transplantation for COVID-19 Treatment in a Puerperium Period in Intensive Care Unit
- 20 November 2021
- Published by Galenos Yayinevi in Turkish Journal of Anaesthesiology and Reanimation
- Vol. 49 (5) , 428-429
Mesenchymal Stem Cell Transplantation for COVID-19 Treatment in a Puerperium Period in Intensive Care Unit
- 1 September 2021
- Published by Kare Publishing in İstanbul Kanuni Sultan Süleyman Tıp dergisi
- Vol. 13 (3) , 213-221
A Comparison of Drug Regimens and Analysis of Effective Factors for Blood Transfusion and Intervention in Spontaneous Rectus Sheath Hematomas
- 1 September 2021
- Published by Kare Publishing in İstanbul Kanuni Sultan Süleyman Tıp dergisi
- Vol. 13 (3) , 213-221
A Comparison of Drug Regimens and Analysis of Effective Factors for Blood Transfusion and Intervention in Spontaneous Rectus Sheath Hematomas
- Open Access
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 45 (SI-1) , 518-529
Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial
Scientific research continues on new preventive and therapeutic strategies against severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). So far, there is no proven curative treatment, and a valid alternative therapeutic approach needs to be developed. This study is designed to evaluate the effect of quercetin in COVID-19 treatment. This was a single-centre, prospective randomized controlled cohort study. Routine care versus QCB (quercetin, vitamin C, bromelain) supplementation was compared between 429 patients with at least one chronic disease and moderate-to-severe respiratory symptoms. Demographic features, signs, laboratory results and drug administration data of patients were recorded. The endpoint was that QCB supplementation was continued throughout the follow-up period from study baseline to discharge, intubation, or death. The most common complaints at the time of hospital admission were fatigue (62.4%), cough (61.1%), anorexia (57%), thirst (53.7%), respiratory distress (51%) and chills (48.3%). The decrease in CRP and ferritin levels was higher in the QCB group (all Ps were < 0.05). In the QCB group, the increase in platelet and lymphocyte counts was higher (all Ps were < 0.05). QCB did not reduce the risk of events during follow-up. Adjustments for statistically significant parameters, including the lung stage, use of favipiravir and presence of comorbidity did not change the results. While there was no difference between the groups in terms of event frequency, the QCB group had more advanced pulmonary findings. QCB supplement is shown to have a positive effect on laboratory recovery. While there was no difference between the groups in terms of event frequency, QCB supplement group had more advanced pulmonar findings, and QCB supplement is shown to have a positive effect on laboratory recovery/results. Therefore, we conclude that further studies involving different doses and plasma level measurements are required to reveal the dose/response relationship and bioavailability of QCB for a better understanding of the role of QCB in the treatment of SARS CoV-2.
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 45 (SI-1) , 518-529
Open AccessTreatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial
Scientific research continues on new preventive and therapeutic strategies against severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). So far, there is no proven curative treatment, and a valid alternative therapeutic approach needs to be developed. This study is designed to evaluate the effect of quercetin in COVID-19 treatment. This was a single-centre, prospective randomized controlled cohort study. Routine care versus QCB (quercetin, vitamin C, bromelain) supplementation was compared between 429 patients with at least one chronic disease and moderate-to-severe respiratory symptoms. Demographic features, signs, laboratory results and drug administration data of patients were recorded. The endpoint was that QCB supplementation was continued throughout the follow-up period from study baseline to discharge, intubation, or death. The most common complaints at the time of hospital admission were fatigue (62.4%), cough (61.1%), anorexia (57%), thirst (53.7%), respiratory distress (51%) and chills (48.3%). The decrease in CRP and ferritin levels was higher in the QCB group (all Ps were < 0.05). In the QCB group, the increase in platelet and lymphocyte counts was higher (all Ps were < 0.05). QCB did not reduce the risk of events during follow-up. Adjustments for statistically significant parameters, including the lung stage, use of favipiravir and presence of comorbidity did not change the results. While there was no difference between the groups in terms of event frequency, the QCB group had more advanced pulmonary findings. QCB supplement is shown to have a positive effect on laboratory recovery. While there was no difference between the groups in terms of event frequency, QCB supplement group had more advanced pulmonar findings, and QCB supplement is shown to have a positive effect on laboratory recovery/results. Therefore, we conclude that further studies involving different doses and plasma level measurements are required to reveal the dose/response relationship and bioavailability of QCB for a better understanding of the role of QCB in the treatment of SARS CoV-2.
- Open Access
- 28 May 2021
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 22 (2) , 149-150
Can we use mesenchymal stem cell transplantation for COVID-19 patients in puerperium period?
- 28 May 2021
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 22 (2) , 149-150
Open AccessCan we use mesenchymal stem cell transplantation for COVID-19 patients in puerperium period?
- Open Access
- 7 August 2020
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 16 (4) , 322-326
Сравнение методов обычной и магнитно-резонансной дефекографии для диагностики дисфункции тазового дна у пациентов с ожирением
Актуальность. Синдром обструкции принадлежит к дисфункциям тазового дна, которые являются причиной неполной эвакуации кала из прямой кишки. Дефекография — первый шаг для диагностики указанного синдрома. Свободный выбор плоскостей визуализации, разрешение и контраст мягких тканей с лучшей модальностью изображения указывают на преимущества этого метода для оценки дисфункции тазового дна. Цель исследования — сравнение обычной и магнитно-резонансной дефекографии у пациентов с синдромом обструкции прямой кишки. Материалы и методы. Двадцать восемь пациентов, страдающих запорами, с января 2015 г. по январь 2020 г. были включены в исследование. Магнитно-резонансная дефекография проводилась через 1–2 недели после обычной дефекографии. Осуществляли сравнительный анализ методов относительно их способности диагностировать патологическое выпячивание передней или задней стенки прямой кишки, нарушающее эвакуаторную функцию кишечника, ректальный пролапс, прямокишечную грыжу, дивертикул прямой кишки. Результаты. Сравнение обычной и магнитно-резонансной дефекографии по их способности диагностировать переднее ректоцеле, инвагинацию внутренней слизистой оболочки и спазм прямой кишки не подтверждает существенных различий между двумя методами. Статистический коэффициент использования двух методов диагностики переднего ректоцеле, инвагинации внутренней слизистой оболочки и спазмов прямой кишки составил соответственно 0,146, 0,007 и 1000. Выводы. Хотя обычная дефекография является золотым стандартом для диагностики ректоцеле, инвагинации внутренней слизистой оболочки и пуборектального спазма, магнитно-резонансная дефекография обладает преимуществами благодаря меньшей радиационной нагрузке, повышенной безопасности и возможности выявления патологии репродуктивной сферы.
- 7 August 2020
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 16 (4) , 322-326
Open AccessСравнение методов обычной и магнитно-резонансной дефекографии для диагностики дисфункции тазового дна у пациентов с ожирением
Актуальность. Синдром обструкции принадлежит к дисфункциям тазового дна, которые являются причиной неполной эвакуации кала из прямой кишки. Дефекография — первый шаг для диагностики указанного синдрома. Свободный выбор плоскостей визуализации, разрешение и контраст мягких тканей с лучшей модальностью изображения указывают на преимущества этого метода для оценки дисфункции тазового дна. Цель исследования — сравнение обычной и магнитно-резонансной дефекографии у пациентов с синдромом обструкции прямой кишки. Материалы и методы. Двадцать восемь пациентов, страдающих запорами, с января 2015 г. по январь 2020 г. были включены в исследование. Магнитно-резонансная дефекография проводилась через 1–2 недели после обычной дефекографии. Осуществляли сравнительный анализ методов относительно их способности диагностировать патологическое выпячивание передней или задней стенки прямой кишки, нарушающее эвакуаторную функцию кишечника, ректальный пролапс, прямокишечную грыжу, дивертикул прямой кишки. Результаты. Сравнение обычной и магнитно-резонансной дефекографии по их способности диагностировать переднее ректоцеле, инвагинацию внутренней слизистой оболочки и спазм прямой кишки не подтверждает существенных различий между двумя методами. Статистический коэффициент использования двух методов диагностики переднего ректоцеле, инвагинации внутренней слизистой оболочки и спазмов прямой кишки составил соответственно 0,146, 0,007 и 1000. Выводы. Хотя обычная дефекография является золотым стандартом для диагностики ректоцеле, инвагинации внутренней слизистой оболочки и пуборектального спазма, магнитно-резонансная дефекография обладает преимуществами благодаря меньшей радиационной нагрузке, повышенной безопасности и возможности выявления патологии репродуктивной сферы.